Immunovant (IMVT) Total Liabilities (2018 - 2026)

Immunovant's Total Liabilities history runs 9 years deep, the most recent figure standing at $104.4 million for Q1 2026.

• Quarterly Total Liabilities rose 51.83% year-over-year to $104.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $104.4 million (up 51.83% YoY) and the FY2026 annual result came in at $104.4 million, up 51.83% from the prior year.
• Total Liabilities was $104.4 million for Q1 2026 at Immunovant, up from $66.3 million in the prior quarter.
• Across five years, Total Liabilities topped out at $104.4 million in Q1 2026 and bottomed at $22.2 million in Q2 2022.
• A 5-year average of $52.5 million and a median of $48.6 million in 2024 frame the typical range for Total Liabilities.
• Peak annual rise in Total Liabilities reached 131.72% in 2023, while the deepest fall reached 22.77% in 2023.
• Immunovant's Total Liabilities stood at $41.6 million in 2022, then retreated by 22.77% to $32.1 million in 2023, then surged by 112.81% to $68.3 million in 2024, then decreased by 3.01% to $66.3 million in 2025, then surged by 57.6% to $104.4 million in 2026.
• Business Quant data shows IMVT's Total Liabilities at $104.4 million in Q1 2026, $66.3 million in Q4 2025, and $63.3 million in Q3 2025.